Compare GSK plc (GSK) vs Herbalife Nutrition Ltd (HLF) Price & Performance

GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.

GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.

HLF trades at $12.45, up 1.72% today, with a bearish technical signal from moving averages. The company shows stable revenue around $5B annually, with a net income margin of 4.66% in 2025. Recent Q1 2026 earnings beat expectations, and the company raised full-year guidance. Positive news includes inclusion in TIME's America's Best Companies 2026 and a major debt refinancing, though insider selling and negative shareholder equity present concerns.

The outlook is mixed: strong brand recognition and earnings beats support upside, but high debt levels and bearish technicals pose risks. Analyst consensus is bullish with 57.7% buy ratings, yet the stock faces headwinds from competitive pressures and reliance on international growth markets like India.